Handelsavisen
prelaunch
Companies Healthcare 6580.TWO
65
6580.TWO TPEx Biotechnology & Medical Research

6580.Two

$16,10
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-851,5 %
ROE
-50,1 %
Net margin
-793,3 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

6580.TWO operates in the healthcare diagnostics segment, providing products and services related to medical testing and diagnostic solutions.

Business. 6580.TWO operates in the healthcare diagnostics segment, providing products and services related to medical testing and diagnostic solutions.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-50,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6580.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6580.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    6580.TWO operates in the healthcare diagnostics segment, providing products and services related to medical testing and diagnostic solutions.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a high level of equity, with total equity of 441,592,000 TWD and total liabilities of 23,644,000 TWD, resulting in a debt-to-equity ratio of 0.01. The company maintains a strong liquidity position, with cash and equivalents amounting to 90,000,000 TWD and a current ratio of 18.53. However, the company is experiencing negative operating and free cash flows, with operating cash flow of -178,474,000 TWD and free cash flow of -215,653,000 TWD.

    Profitability metrics indicate significant underperformance, with a return on equity of -0.5008 and a return on assets of -0.4753. These figures are well below the industry median for return on equity and return on assets, suggesting that the company is not generating returns at a level typical for its industry.

    The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no additional geographic or segment breakdown provided in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates.

    The company's growth trajectory is currently negative, with a net loss of 221,128,000 TWD and an operating loss of 237,356,000 TWD. There are no immediate filing-based liquidity or dilution flags, and the risk assessment indicates low liquidity and dilution risk.

    Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company has not issued any new shares or taken on additional debt in the latest reporting period.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 18.53 and significant cash reserves.
    • The company is experiencing significant losses, with a net loss of 221,128,000 TWD and an operating loss of 237,356,000 TWD.
    • The company's capital structure is heavily equity-based, with a debt-to-equity ratio of 0.01.
    • The company's profitability metrics are below industry medians, indicating underperformance.
    • The company has no immediate liquidity or dilution risks, but its negative cash flows may impact future operations.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $16,10
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $441.6M
    Net cash
    $84.1M
    Current ratio
    18.5
    Debt / equity
    0.0
    ROA
    -47.5%
    ROE
    -50.1%
    Cash conversion
    81.0%
    CapEx / revenue
    -4.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-851,5 %Below median
    Net Margin-793,3 %Below median
    ROE-50,1 %Below median
    Capex / Rev-4,1 %Above median
    D/E0,01Above median
    Cash Conv0,81Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 6580.TWO Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6580.TWOCanonical
    TPEx · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage